Aurobindo Pharma’s Subsidiary Launches Pomalidomide in US Market
Filing Summary
Aurobindo Pharma Limited announced that its wholly owned subsidiary, Eugia Pharma Specialities Limited, has launched Pomalidomide Capsules in the US market. The capsules are available in 1 mg, 2 mg, 3 mg, and 4 mg dosages and are the generic equivalent of Pomalyst® Capsules by BMS Pharmaceuticals Corp. Eugia Pharma was among the First-to-File ANDA applicants for this product. The estimated market size for Pomalidomide Capsules in the US is approximately USD 3.3 billion, according to IQVIA MAT data for the twelve months ending January 2026.
Aurobindo Pharma Limited has announced the launch of Pomalidomide Capsules in the US market through its wholly owned subsidiary, Eugia Pharma Specialities Limited. The capsules are available in dosages of 1 mg, 2 mg, 3 mg, and 4 mg. These products are the generic equivalent of Pomalyst® Capsules, manufactured by BMS Pharmaceuticals Corp. Eugia Pharma Specialities Limited was one of the First-to-File (FTF) ANDA applicants for this product.
The estimated market size for Pomalidomide Capsules in the US is approximately USD 3.3 billion, according to IQVIA MAT data for the twelve months ending January 2026. The financial terms related to the launch were not disclosed in the filing. The capsules will be manufactured at Eugia Unit-I, although specific production capacities or financial arrangements were not detailed.
The scope of the launch includes the introduction of a third-generation immunomodulatory drug (IMiD) used in combination with dexamethasone and sometimes bortezomib. This drug is utilized for the treatment of relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma. The filing does not provide additional technical specifications or details regarding distribution channels.
According to the filing, the US market for Pomalidomide Capsules is significant, with an estimated market size of approximately USD 3.3 billion. This launch positions Eugia Pharma Specialities Limited in a competitive market segment. The filing does not elaborate on the competitive landscape or market share expectations.
The filing does not specify the exact timeline for the product’s availability in the market or any associated milestones. However, the launch announcement was made on March 4, 2026. The filing also does not mention any collaborations or partnerships related to this launch.
Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients globally in over 150 countries. The company operates over 30 manufacturing and packaging facilities approved by leading regulatory agencies, including USFDA and UK MHRA.